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onary stent implantation is associated with higher risk for bleeding.
Second-generation drug-eluting stents (G2-DES), cobalt-chromium
everolimus-eluting stent (CoCr-EES) in particular, are reported to
have lower risk for stent thrombosis (ST) compared with ﬁrst gener-
ation DES or bare-metal stents. Therefore, the optimal DAPT duration
after CoCr-EES implantation could be shorter than 6-12 months
currently recommended in the guidelines. However, there has been
no prospective study evaluating DAPT duration shorter than 6 months
after CoCr-EES implantation.
METHODS STOPDAPT study is a prospective multicenter single-arm
registry enrolling patients who agreed to follow the 3-month DAPT
protocol (discontinuation of clopidogrel at 2- to 4-month and aspirin
monotherapy thereafter) after successful CoCr-EES implantation. The
primary endpoint was a composite of cardiovascular (CV) death,
myocardial infarction (MI), stroke, deﬁnite ST and TIMI major/minor
bleeding at 1-year. As a historical comparison group, we selected the
CoCr-EES group in the RESET trial comparing CoCr-EES with sirolimus-
eluting stent conducted in 2010, where nearly 90% of patients had
continued DAPT at 1-year. With the 6.6% of performance goal based on
the event rate of 4.4% in the RESET trial, a total of 1500 patients would
yield 95% power at a level of one-sided type 1 error of 0.025.
RESULTS Between September 2012 and October 2013, a total of 1525
patients were enrolled in the study from 58 participating centers across
Japan, and 1-year follow-up was completed in 1519 patients (99.6%).
Thienopyridine was discontinued within 4-month in 1444 patients
(94.7%). The event rates beyond 3-month were very low (CV death:
0.5%, MI: 0.1%, deﬁnite/probable ST: 0%, stroke: 0.7%, and TIMI ma-
jor/minor bleeding: 0.8%). Cumulative 1-year incidence of the primary
endpoint was 2.8% (Upper 97.5% conﬁdence interval [CI] 3.6%), which
was lower than the pre-deﬁned performance goal of 6.6% (P<0.0001).
Compared to CoCr-EES group in the RESET trial, cumulative incidence
of the primary endpoint tended to be lower in the STOPDAPT than in
the RESET (2.8% versus 4.0%, P¼0.06) and adjusted hazard ratio was
0.64 (95%CI 0.42-0.95, P¼0.03). The cumulative incidence of deﬁnite/
probable ST was lower in the STOPDAPT than in the RESET (0 patient
[0%] versus 5 patients [0.3%], P¼0.03).
CONCLUSIONS Stopping DAPT at 3-month after CoCr-EES implanta-
tion was at least as safe as the prolonged DAPT regimen adopted in the
previous randomized trial.
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26Hospital Germans Trias i Pujol, Badalona, SpainBACKGROUND Primary angioplasty is the best reperfusion treatment
in ST elevated myocardial infarction. The prevalence of very elderly
patients (> 75 years) undergoing primary angioplasty is progressively
increasing as population is ageing. The beneﬁt of the new generation
drug-eluting stents over bare metal stents in terms of safety and efﬁ-
cacy is unknown for this important subgroup of patients in this setting.
METHODS Retrospective consecutive registry conducted in 31 centers
of patients > 75 years with ST elevation myocardial infarction un-
dergoing primary angioplasty.
RESULTS A total of 3,126 pts have been included, 2,132 (68.2%) treated
with BMS and 994 (31.8%) treated with new generation DES. After exclu-
sion of patients presenting with cardiogenic shock or requiring cardiac
surgery for mechanical complications (14%) a propensity score matching
was performed yielding two comparable groups of 580 patients each with
well- balanced baseline clinical or angiographic characteristics. Outcomes
at 12 months were: cardiac death and MI 10.2% with BMS and 5.2% with
DES (p¼0.01), TLR was 3.8% with BMS and 1.5% with DES (p¼0.04), deﬁ-
nite or probable thrombosis 4.3% with BMS and 2.4% with DES (p¼0.06),
deﬁnite thrombosis 3.7% with BMS and 1.3% with DES (p¼0.03) and
bleeding BARC > 2 0.7% with BMS and 1.2% with DES (p¼0.3).
CONCLUSIONS In this registry of patients over 75 years undergoing
primary angioplasty, most were treated with BMS. After propensity
score matching clinical outcomes were signiﬁcantly better in those
treated with new DES without signiﬁcant increase in severe bleeding
events in follow up.
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BACKGROUND Percutaneous intervention of distal bifurcation un-
protected left main coronary arteries (UPLMCA) are technically
demanding with less favorable outcomes. The optimal treatment
strategy to improve long-term outcomes is uncertain.
METHODS Studies comparing simple approach (provisional stenting)
versus complex stenting (elective two stent technique) were consid-
ered for inclusion. A search strategy using Medline, Embase, Cochrane
database and the proceedings of the international meetings were
included. Information about study design, inclusion criteria and
sample characteristics were extracted. Meta-analysis of pooled event
rates was compared between these two stenting approaches.
RESULTS 16 studies including 5978 patients who were treated with
simple versus complex bifurcation stenting for UPLMCA bifurcations
were analyzed. There were no differences in the rates of myocardial
infarction (OR 0.81, CI 0.15-4.2), stent thrombosis (OR 0.8, CI 0.2-1.7),
target vessel revascularization (OR 0.4, CI 0.6-2.7) or mortality (OR
0.92, CI 0.3-2.8) between simple versus complex stenting approaches
at 1 year. However, at 5 years of follow-up there was a signiﬁcant
difference in the rates of target vessel revascularization (OR 0.4, CI
0.3-0.7, p¼0.001) favoring the simple approach. There was no differ-
ence in the mortality (OR 0.94, CI 0.75-1.19), stent thrombosis (OR
0.83, 0.32-2.1) or myocardial infarction (OR 1.16, CI 0.7-1.7) using
either approach at 5 years of follow-up.
CONCLUSIONS Percutaneous intervention for UPLMCA should favor
a simple approach over complex approach to optimize long-term
outcomes.
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BACKGROUND Stent fracture (SF) after drug-eluting stent implanta-
tion has been reported to be associated with in-stent restenosis (ISR),
